These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

770 related articles for article (PubMed ID: 31209302)

  • 1. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease.
    Adams D; Koike H; Slama M; Coelho T
    Nat Rev Neurol; 2019 Jul; 15(7):387-404. PubMed ID: 31209302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease-Modifying Drugs Extend Survival in Hereditary Transthyretin Amyloid Polyneuropathy.
    Ueda M; Misumi Y; Nomura T; Tasaki M; Yamakawa S; Obayashi K; Yamashita T; Ando Y
    Ann Neurol; 2024 Feb; 95(2):230-236. PubMed ID: 38053464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The neuropathy in hereditary transthyretin amyloidosis: A narrative review.
    Tozza S; Severi D; Spina E; Iovino A; Aruta F; Ruggiero L; Dubbioso R; Iodice R; Nolano M; Manganelli F
    J Peripher Nerv Syst; 2021 Jun; 26(2):155-159. PubMed ID: 33960565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hereditary transthyretin amyloidosis overview.
    Manganelli F; Fabrizi GM; Luigetti M; Mandich P; Mazzeo A; Pareyson D
    Neurol Sci; 2022 Dec; 43(Suppl 2):595-604. PubMed ID: 33188616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis.
    Coelho T; Maurer MS; Suhr OB
    Curr Med Res Opin; 2013 Jan; 29(1):63-76. PubMed ID: 23193944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A low amyloidogenic E61K transthyretin mutation may cause familial amyloid polyneuropathy.
    Murakami T; Yokoyama T; Mizuguchi M; Toné S; Takaku S; Sango K; Nishimura H; Watabe K; Sunada Y
    J Neurochem; 2021 Mar; 156(6):957-966. PubMed ID: 32852783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Expression of Chemokines Is Downregulated in a Pre-Clinical Model of TTR V30M Amyloidosis.
    Moreira J; Costelha S; Saraiva M; Saraiva MJ
    Front Immunol; 2021; 12():650269. PubMed ID: 34093538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology.
    Skrahina V; Grittner U; Beetz C; Skripuletz T; Juenemann M; Krämer HH; Hahn K; Rieth A; Schaechinger V; Patten M; Tanislav C; Achenbach S; Assmus B; Knebel F; Gingele S; Skrahin A; Hartkamp J; Förster TM; Roesner S; Pereira C; Rolfs A
    Ann Med; 2021 Dec; 53(1):1787-1796. PubMed ID: 34658264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis.
    Carroll A; Dyck PJ; de Carvalho M; Kennerson M; Reilly MM; Kiernan MC; Vucic S
    J Neurol Neurosurg Psychiatry; 2022 Jun; 93(6):668-678. PubMed ID: 35256455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.
    Gertz MA; Scheinberg M; Waddington-Cruz M; Heitner SB; Karam C; Drachman B; Khella S; Whelan C; Obici L
    Expert Rev Clin Pharmacol; 2019 Aug; 12(8):701-711. PubMed ID: 31268366
    [No Abstract]   [Full Text] [Related]  

  • 12. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial.
    Waddington-Cruz M; Ackermann EJ; Polydefkis M; Heitner SB; Dyck PJ; Barroso FA; Wang AK; Berk JL; Dyck PJB; Monia BP; Hughes SG; Tai L; Jesse Kwoh T; Jung SW; Coelho T; Benson MD; Gertz MA
    Amyloid; 2018 Sep; 25(3):180-188. PubMed ID: 30169969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hereditary transthyretin-related amyloidosis.
    Finsterer J; Iglseder S; Wanschitz J; Topakian R; Löscher WN; Grisold W
    Acta Neurol Scand; 2019 Feb; 139(2):92-105. PubMed ID: 30295933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver transplantation in transthyretin amyloidosis: issues and challenges.
    Carvalho A; Rocha A; Lobato L
    Liver Transpl; 2015 Mar; 21(3):282-92. PubMed ID: 25482846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotypic and phenotypic presentation of transthyretin-related familial amyloid polyneuropathy (TTR-FAP) in Turkey.
    Durmuş-Tekçe H; Matur Z; Mert Atmaca M; Poda M; Çakar A; Hıdır Ulaş Ü; Oflazer-Serdaroğlu P; Deymeer F; Parman YG
    Neuromuscul Disord; 2016 Jul; 26(7):441-6. PubMed ID: 27238058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transthyretin Amyloid Neuropathy: The Schwann Cell Hypothesis.
    Murakami T; Sunada Y
    Adv Exp Med Biol; 2019; 1190():371-378. PubMed ID: 31760657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wild-type transthyretin significantly contributes to the formation of amyloid fibrils in familial amyloid polyneuropathy patients with amyloidogenic transthyretin Val30Met.
    Tsuchiya-Suzuki A; Yazaki M; Kametani F; Sekijima Y; Ikeda S
    Hum Pathol; 2011 Feb; 42(2):236-43. PubMed ID: 21056899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
    Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T
    J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 39.